GCK, a new therapeutic target for undruggable RAS in myeloma treatment

Description

The project aims to investigate GCK as a therapeutic target for RAS-mutated multiple myeloma (MM), where current treatments are lacking. RAS pathway mutations are common in MM, driving disease progression, yet no RAS inhibitors are clinically available. GCK, a key player in B cell differentiation, has been found critical for MM cell survival and growth, particularly in RAS-mutated MM. Inhibition of GCK leads to MM cell death and overcomes resistance to current therapies like IMiDs. The project seeks to correlate RAS mutation status with the effectiveness of GCK inhibition in MM treatment and elucidate the mechanisms by which GCK inhibition overcomes IMiDs resistance. These findings could pave the way for personalized MM treatment strategies targeting specific RAS mutations and overcoming resistance.